Table 3.
ADCs in late clinical development with a small molecule drug payload and their key features.
| ADC Name | Target | Payload | Linker | Phase |
|---|---|---|---|---|
| BAT8001 | HER-2 | Maytansinoid | non-cleavable | 3 |
| disitamab vedotin | HER-2 | MMAE | Val-Cit-PABA | 3 |
| DS-1062a | TROP-2 | DXd | Gly-Gly-Phe-Gly | 3 |
| loncastuximab Tesirine | CD19 | SG3199 | Val-Ala-PABA | 3 |
| mirvetuximab soravtansine | FOLR-α | DM4 | sulfo-SPDB 1 | 3 |
| ZRC-3256 2 | HER-2 | DM1 | SMCC 3 | 3 |
| ANG1005 4 | LRP1 | Paclitaxel | covalent | 3 |
| SAR408701 | CEACAM5 | DM4 | SPDB 5 | 3 |
| TAA013 | HER-2 | DM1 | SMCC 3 | 3 |
| trastuzumab duocarmazine | HER-2 | seco-DUBA | Val-Cit-PABA | 3 |
| tisotumab vedotin | TF | MMAE | Val-Cit-PABA | 3 |
| ARX788 | HER-2 | Amberstatin269 | oxime | 2/3 |
| ABBV-3373 | TNF-α | Steroid | Ala-Ala-PABA | 2 |
| anetumab ravtansine | MSLN | DM4 | SPDB 5 | 2 |
| BA3011 | Axl | MMAE | cleavable | 2 |
| camidanlumab Tesirine | CD25 | SG3199 | Val-Ala-PABA | 2 |
| labetuzumab Govitecan | CEACAM5 | SN-38 | CL2A 6 | 2 |
| ladiratuzumab vedotin | LIV-1 | MMAE | Val-Cit | 2 |
| MRG003 | EGFR | MMAE | Val-Cit-PABA | 2 |
| naratuximab emtansine | CD37 | DM1 | SMCC 3 | 2 |
| patritumab Deruxtecan | HER-3 | DXd | Gly-Gly-Phe-Gly | 2 |
| praluzatamab ravtansine | CD166 | DM4 | SPDB 5 | 2 |
| telisotuzumab vedotin | c-MET | MMAE | Val-Cit-PABA | 2 |
| VLS-101 | ROR1 | MMAE | Val-Cit-PABA | 2 |
1 4-thio-2-sulfobutanoyl. 2 ZRC-3256 is a generic of 3. 3 4-(3-thio-N-maleimidomethyl)cyclohexane-1-carboxyl. 4 the delivery agent is not an antibody but the Angiopep-2 peptide. 5 4-thiobutanoyl. 6 SPDB-based PEG containing a cleavable Lys-PABA linker.